In the randomized phase II CITYSKAPE study, chemotherapy-naive patients with relapsed or metastatic PD-L1-positive non-small-cell lung cancer (NSCLC) were randomized to receive tiragolumab (600 mg) plus atezolizumab (1200 mg) or placebo plus atezolizumab intravenously once every 3 weeks. This evidence concerns the gene CD274 and non-small cell lung carcinoma.